Gowans Duncan, O'Sullivan Alan, Rollinson Sara, Roddam Phillipa, Groves Mike, Fegan Chris, Morgan Gareth, Bowen David
Department of Molecular and Cellular Pathology, Ninewells Hospital, Dundee DD1 9SY, Scotland, UK.
Br J Haematol. 2002 Jun;117(3):541-5. doi: 10.1046/j.1365-2141.2002.03452.x.
An autoimmune mechanism in the pathogenesis of myelodysplastic syndrome (MDS) is suggested by response to immunosuppression, with CD8+ T-lymphocytes implicated in the haematopoietic suppression. We therefore sought evidence for human leucocyte antigen (HLA) restriction and variant frequency differences in selected polymorphisms at the loci for the immunomodulatory cytokines, tumour necrosis factor alpha (TNF-alpha), lymphotoxin-alpha (LT-alpha) and interleukin 10 (IL-10) in patients with MDS and acute myeloid leukaemia (AML) compared with normal controls. DNA from 150 MDS/AML patients [24 AML, 53 refractory anaemia (RA), 25 RA with excess blasts (RAEB), four RAEB in transformation (RAEBt), 21 sideroblastic leukaemia, 22 chronic myelomonocytic leukaemia] was screened. Control data was from Scottish blood donors (HLA class I/II), healthy General Practitioner-based subjects (TNF-alpha/LT-alpha) and published values (IL-10). HLA class I/II haplotypes were determined using sequence-specific primers. Polymorphisms were assayed at TNF-alpha -308, LT-alpha +252 and IL10 -824, -597 and -1082 loci. Variant frequencies of common haplotypes at HLA class I and II, high-/low-producer TNF-alpha/LT-alpha and IL-10 loci were not different between patients and controls or within the French-American-British, International Prognostic Scoring System or cytogenetic subgroups and were not associated with altered survival for MDS/AML patients. TNF2 allele frequency was greater in the MDS/AML cohort (chi2 = 6.593, P < 0.05) but the biological significance was uncertain in the absence of an increased high-producer TNF-alpha/LT-alpha haplotype frequency. We can find no genetic influence for these polymorphisms in HLA class I/II, TNF-alpha/LT-alpha and IL-10 loci on either predisposition or disease progression in MDS/AML.
骨髓增生异常综合征(MDS)发病机制中的自身免疫机制可由免疫抑制反应提示,其中CD8 + T淋巴细胞与造血抑制有关。因此,我们寻找证据,以探究与正常对照组相比,MDS和急性髓系白血病(AML)患者中免疫调节细胞因子、肿瘤坏死因子α(TNF-α)、淋巴毒素α(LT-α)和白细胞介素10(IL-10)基因座上选定多态性的人类白细胞抗原(HLA)限制性和变异频率差异。对150例MDS/AML患者[24例AML、53例难治性贫血(RA)、25例伴有过多原始细胞的RA(RAEB)、4例转化中的RAEB(RAEBt)、21例铁粒幼细胞性白血病、22例慢性粒单核细胞白血病]的DNA进行了筛查。对照数据来自苏格兰献血者(HLA I/II类)、以全科医生为基础的健康受试者(TNF-α/LT-α)和已发表的值(IL-10)。使用序列特异性引物确定HLA I/II类单倍型。在TNF-α -308、LT-α +252和IL10 -824、-597和-1082基因座检测多态性。患者和对照组之间,以及法国-美国-英国、国际预后评分系统或细胞遗传学亚组内,HLA I类和II类常见单倍型、高/低产生者TNF-α/LT-α和IL-10基因座的变异频率没有差异,并且与MDS/AML患者的生存改变无关。MDS/AML队列中TNF2等位基因频率更高(χ2 = 6.593,P < 0.05),但在高产TNF-α/LT-α单倍型频率未增加的情况下,其生物学意义尚不确定。我们发现这些HLA I/II类、TNF-α/LT-α和IL-10基因座的多态性对MDS/AML的易感性或疾病进展没有遗传影响。